Eps3.10 Patient Demographics and Baseline Disease Characteristics in a Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 2b Study of Lenabasum, a Selective Cannabinoid Receptor Type 2 Agonist, in Cystic Fibrosis